{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:55:34Z","timestamp":1761897334928},"reference-count":236,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are three different marginal zone lymphoma (MZLs) entities: the extranodal MZL of mucosa- associated lymphoid tissue, the splenic MZL, and the nodal MZL. The 3 MZLs share common lesions (trisomies of chromosomes 3 and 18, deletions at 6q23), and alterations of the nuclear factor \u03baB pathway are frequent events in all of them, but they also differ in the presence of recurrent translocations, mutations affecting the NOTCH pathway, and the transcription factor Kruppel-like factor 2 (<jats:italic toggle=\"yes\">KLF2)<\/jats:italic>or the receptor-type protein tyrosine phosphatase delta (<jats:italic toggle=\"yes\">PTPRD<\/jats:italic>). This review outlines the most recent and main advances in our understanding of the genetics and biology of MZLs and summarizes the clinical activity of the novel therapeutic approaches targeting the main druggable pathways. The current principles of the standard management of MZL at different anatomic sites are also discussed.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000463","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T01:13:41Z","timestamp":1595466821000},"page":"336-347","source":"Crossref","is-referenced-by-count":8,"title":["Marginal Zone Lymphomas"],"prefix":"10.1097","volume":"26","author":[{"given":"Francesco","family":"Bertoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[{"name":"Internal Medicine I, Oncology, Medical University of Vienna, Vienna, Austria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nri3383","article-title":"Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes","volume":"13","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1182\/blood-2013-07-515155","article-title":"Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?","volume":"123","year":"2014","journal-title":"Blood"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/bjh.13052","article-title":"Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features","volume":"167","year":"2014","journal-title":"Br J Haematol"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/bloodadvances.2018019760","article-title":"CBL-MZ is not a single biological entity: evidence from genomic analysis and prolonged clinical follow-up","volume":"2","year":"2018","journal-title":"Blood Adv"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/hon.2361","article-title":"Detection of L265P MYD-88 mutation in a series of clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ)","volume":"35","year":"2017","journal-title":"Hematol Oncol"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.beha.2016.07.002","article-title":"Epidemiology and environmental aspects of marginal zone lymphomas","volume":"30","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1158\/1078-0432.CCR-14-0496","article-title":"Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas","volume":"20","year":"2014","journal-title":"Clin Cancer Res"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/jnci\/djh102","article-title":"Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas","volume":"96","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1200\/JCO.2005.07.083","article-title":"Regression of ocular adnexal lymphoma after Chlamydia psittaci\u2013eradicating antibiotic therapy","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib13-20230924","first-page":"547","article-title":"Is there an association between ocular adnexal lymphoma and infection with Chlamydia psittaci? The University of Rochester experience","volume":"30","year":"2005","journal-title":"Leuk Res"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/path.1984","article-title":"Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions","volume":"209","year":"2006","journal-title":"J Pathol"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2141.2005.05943.x","article-title":"Absence of Chlamydia psittaci in ocular adnexal lymphoma from Japanese patients","volume":"132","year":"2006","journal-title":"Br J Haematol"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hon.768","article-title":"Association between Helicobacter pylori infection and MALT-type lymphoma of the ocular adnexa: clinical and therapeutic implications","volume":"24","year":"2006","journal-title":"Hematol Oncol"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.leukres.2005.12.003","article-title":"No evidence for an association of ocular adnexal lymphoma with Chlamydia psittaci in a cohort of patients from the Netherlands","volume":"30","year":"2006","journal-title":"Leuk Res"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/10428190600908174","article-title":"Low prevalence of Chlamydia psittaci in ocular adnexal lymphomas from Cuban patients","volume":"48","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1634\/theoncologist.2011-0108","article-title":"Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomas","volume":"16","year":"2011","journal-title":"Oncologist"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0046-8177(00)80233-6","article-title":"Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin","volume":"31","year":"2000","journal-title":"Hum Pathol"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0190-9622(97)80405-7","article-title":"Borrelia burgdorferi\u2013associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a","volume":"36","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa031887","article-title":"Immunoproliferative small intestinal disease associated with Campylobacter jejuni","volume":"350","year":"2004","journal-title":"N Engl J Med"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2004-07-2755","article-title":"Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms","volume":"105","year":"2005","journal-title":"Blood"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/bjh.12703","article-title":"Prevalence of Achromobacter xylosoxidans in pulmonary mucosa\u2013associated lymphoid tissue lymphoma in different regions of Europe","volume":"164","year":"2014","journal-title":"Br J Haematol"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1182\/blood.V84.9.3047.3047","article-title":"Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia","volume":"84","year":"1994","journal-title":"Blood"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2141.1994.tb05036.x","article-title":"Hepatitis C virus infection in patients with non-Hodgkin\u2019s lymphoma","volume":"88","year":"1994","journal-title":"Br J Haematol"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/asheducation-2014.1.590","article-title":"Hepatitis C virus\u2013associated B-cell non-Hodgkin lymphomas","volume":"2014","year":"2014","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4254\/wjh.v8.i2.107","article-title":"Hepatitis C virus and non-Hodgkin's lymphomas: meta-analysis of epidemiology data and therapy options","volume":"8","year":"2016","journal-title":"World J Hepatol"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/annonc\/mdx635","article-title":"From hepatitis C virus infection to B-cell lymphoma","volume":"29","year":"2018","journal-title":"Ann Oncol"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1023\/A:1008396618983","article-title":"Gastric MALT lymphoma: from concept to cure","volume":"10","year":"1999","journal-title":"Ann Oncol"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph consortium","volume":"111","year":"2008","journal-title":"Blood"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/annonc\/mdn049","article-title":"Chronic autoimmune thyroiditis (Hashimoto's thyroiditis) in patients with MALT lymphoma","volume":"19","year":"2008","journal-title":"Ann Oncol"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/jncimonographs\/lgu011","article-title":"Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph non-Hodgkin lymphoma subtypes project","volume":"2014","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.12730","article-title":"Incidence of marginal zone lymphoma in the United States, 2001\u20132009 with a focus on primary anatomic site","volume":"165","year":"2014","journal-title":"Br J Haematol"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00277-018-3501-8","article-title":"Burden of illness of follicular lymphoma and marginal zone lymphoma","volume":"98","year":"2019","journal-title":"Ann Hematol"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004\u20132014: sub-type analyses from the UK's Haematological Malignancy Research Network","volume":"112","year":"2015","journal-title":"Br J Cancer"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"e12120","DOI":"10.1097\/MD.0000000000012120","article-title":"Epidemiologic characteristics of malignant lymphoma in Hubei, China: a single-center 5-year retrospective study","volume":"97","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s12185-018-2403-9","article-title":"Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial","volume":"107","year":"2018","journal-title":"Int J Hematol"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1746-1596-6-77","article-title":"Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution","volume":"6","year":"2011","journal-title":"Diagn Pathol"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","article-title":"Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification","volume":"138","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ajh.21824","article-title":"Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification","volume":"85","year":"2010","journal-title":"Am J Hematol"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.12659","article-title":"Differences in incidence and trends of haematological malignancies in Japan and the United States","volume":"164","year":"2014","journal-title":"Br J Haematol"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canep.2016.02.007","article-title":"Subtype-specific incidence rates of lymphoid malignancies in Hong Kong compared to the United States, 2001\u20132010","volume":"42","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3109\/10428194.2013.764421","article-title":"Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites","volume":"54","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/annonc\/mdp402","article-title":"Decreasing incidence of gastric MALT lymphomas in the era of anti\u2013Helicobacter pylori interventions: results from a population-based study on extranodal marginal zone lymphomas","volume":"21","year":"2010","journal-title":"Ann Oncol"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00277-014-2298-3","article-title":"Antibiotic treatment as sole management of Helicobacter pylori\u2013negative gastric MALT lymphoma: a single center experience with prolonged follow-up","volume":"94","year":"2015","journal-title":"Ann Hematol"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1136\/gutjnl-2014-307389","article-title":"Helicobacter pylori infection in gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma: a re-evaluation","volume":"63","year":"2014","journal-title":"Gut"},{"key":"bib49-20230924","first-page":"1190","article-title":"Ongoing mutation in MALT lymphoma immunoglobulin gene suggests that antigen stimulation plays a role in the clonal expansion","volume":"10","year":"1996","journal-title":"Leukemia"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.beha.2016.09.004","article-title":"Molecular pathogenesis of splenic and nodal marginal zone lymphoma","volume":"30","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood.V99.4.1299","article-title":"Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course","volume":"99","year":"2002","journal-title":"Blood"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1046\/j.1365-2141.1997.1392954.x","article-title":"Immunoglobulin heavy chain diversity genes rearrangement pattern indicates that MALT-type gastric lymphoma B cells have undergone an antigen selection process","volume":"97","year":"1997","journal-title":"Br J Haematol"},{"key":"bib53-20230924","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood.V98.3.781","article-title":"Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes","volume":"98","year":"2001","journal-title":"Blood"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2141.2010.08347.x","article-title":"Immunogenetics features and genomic lesions in splenic marginal zone lymphoma","volume":"151","year":"2010","journal-title":"Br J Haematol"},{"key":"bib55-20230924","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/blood.V99.7.2541","article-title":"Molecular follow-up in gastric mucosa\u2013associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial","volume":"99","year":"2002","journal-title":"Blood"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1182\/blood.V91.7.2381","article-title":"Mutation analysis of the rearranged immunoglobulin heavy chain genes of marginal zone cell lymphomas indicates an origin from different marginal zone B lymphocyte subsets","volume":"91","year":"1998","journal-title":"Blood"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/path.5209","article-title":"Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferations","volume":"247","year":"2019","journal-title":"J Pathol"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/path.4933","article-title":"Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma","volume":"243","year":"2017","journal-title":"J Pathol"},{"key":"bib59-20230924","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.semcancer.2013.11.005","article-title":"Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type","volume":"24","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.2010.025437","article-title":"Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma","volume":"95","year":"2010","journal-title":"Haematologica"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood-2009-06-228015","article-title":"Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins","volume":"115","year":"2010","journal-title":"Blood"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2005-04-1722","article-title":"Influence of antigen on the development of MALT lymphoma","volume":"107","year":"2006","journal-title":"Blood"},{"key":"bib63-20230924","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1155\/1998\/18679","article-title":"CD40 ligand and autoantigen are involved in the pathogenesis of low-grade B-cell lymphomas of mucosa-associated lymphoid tissue","volume":"6","year":"1998","journal-title":"Dev Immunol"},{"key":"bib64-20230924","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood-2011-03-341651","article-title":"Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly- and self-reactive antibodies with similar reactivity","volume":"118","year":"2011","journal-title":"Blood"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2010-01-264275","article-title":"Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome","volume":"117","year":"2011","journal-title":"Blood"},{"key":"bib66-20230924","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20120904","article-title":"The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development","volume":"209","year":"2012","journal-title":"J Exp Med"},{"key":"bib67-20230924","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1182\/blood.V124.21.705.705","article-title":"The coding genome of nodal marginal zone lymphoma reveals recurrent molecular alterations of PTPRD and other Jak\/Stat signaling genes","volume":"124","year":"2014","journal-title":"Blood"},{"key":"bib68-20230924","doi-asserted-by":"crossref","first-page":"17038","DOI":"10.18632\/oncotarget.14928","article-title":"The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib69-20230924","doi-asserted-by":"crossref","first-page":"62627","DOI":"10.18632\/oncotarget.11548","article-title":"Recurrent mutations in NF-kappaB pathway components, KMT2D, and NOTCH1\/2 in ocular adnexal MALT-type marginal zone lymphomas","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"bib70-20230924","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/sj.leu.2403909","article-title":"Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases","volume":"19","year":"2005","journal-title":"Leukemia"},{"key":"bib71-20230924","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.3324\/haematol.2018.214957","article-title":"Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses","volume":"104","year":"2019","journal-title":"Haematologica"},{"journal-title":"Hematol Oncol","article-title":"High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas","year":"2020","key":"bib72-20230924"},{"key":"bib73-20230924","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1182\/blood-2008-08-174110","article-title":"The NF-\u039aB negative regulator TNFAIP3 (A20) is commonly inactivated by somatic mutations and genomic deletions in marginal zone B-cell lymphomas","volume":"113","year":"2009","journal-title":"Blood"},{"key":"bib74-20230924","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2008-12-194852","article-title":"TNFAIP3\/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas","volume":"114","year":"2009","journal-title":"Blood"},{"key":"bib75-20230924","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1182\/blood-2011-06-359166","article-title":"Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma","volume":"118","year":"2011","journal-title":"Blood"},{"key":"bib76-20230924","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1084\/jem.20120910","article-title":"Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma","volume":"209","year":"2012","journal-title":"J Exp Med"},{"key":"bib77-20230924","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing","volume":"21","year":"2015","journal-title":"Clin Cancer Res"},{"key":"bib78-20230924","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1182\/blood.V93.11.3601","article-title":"The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas","volume":"93","year":"1999","journal-title":"Blood"},{"key":"bib79-20230924","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0092-8674(00)80957-5","article-title":"Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types","volume":"96","year":"1999","journal-title":"Cell"},{"key":"bib80-20230924","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood-2002-09-2963","article-title":"T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma","volume":"101","year":"2003","journal-title":"Blood"},{"key":"bib81-20230924","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/sj.leu.2403644","article-title":"T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma","volume":"19","year":"2005","journal-title":"Leukemia"},{"key":"bib82-20230924","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1097\/01.pas.0000213275.60962.2a","article-title":"The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America","volume":"30","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"bib83-20230924","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1038\/sj.leu.2403122","article-title":"Translocations t(11;18)(q21;q21) and t(14;18)(q32;q21) are the main chromosomal abnormalities involving MLT\/MALT1 in MALT lymphomas","volume":"17","year":"2003","journal-title":"Leukemia"},{"key":"bib84-20230924","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2002-11-3502","article-title":"Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H. pylori in gastric MALT lymphoma","volume":"102","year":"2003","journal-title":"Blood"},{"key":"bib85-20230924","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/modpathol.2008.74","article-title":"FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control","volume":"21","year":"2008","journal-title":"Mod Pathol"},{"key":"bib86-20230924","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3324\/haematol.2018.191601","article-title":"Novel GPR34 and CCR6 mutation and distinct genetic profiles in MALT lymphomas of different sites","volume":"103","year":"2018","journal-title":"Haematologica"},{"key":"bib87-20230924","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1182\/blood-2002-10-3167","article-title":"High incidence of t(11;18)(q21;q21) in Helicobacter pylori\u2013negative gastric MALT lymphoma","volume":"101","year":"2003","journal-title":"Blood"},{"key":"bib88-20230924","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/gast.2002.33047","article-title":"T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication","volume":"122","year":"2002","journal-title":"Gastroenterology"},{"key":"bib89-20230924","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2006.05.6150","article-title":"Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib90-20230924","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/sj.leu.2404244","article-title":"Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation","volume":"20","year":"2006","journal-title":"Leukemia"},{"key":"bib91-20230924","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood.V87.1.299.299","article-title":"Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features","volume":"87","year":"1996","journal-title":"Blood"},{"key":"bib92-20230924","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3324\/haematol.2011.040402","article-title":"Genomic profiles of MALT lymphomas: variability across anatomic sites","volume":"96","year":"2011","journal-title":"Haematologica"},{"key":"bib93-20230924","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3324\/haematol.2011.052639","article-title":"T(X;14)(p11.4;q32.33) is recurrent in marginal zone lymphoma and up-regulates GPR34","volume":"97","year":"2012","journal-title":"Haematologica"},{"key":"bib94-20230924","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1182\/blood-2011-11-389908","article-title":"T(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth","volume":"120","year":"2012","journal-title":"Blood"},{"key":"bib95-20230924","doi-asserted-by":"crossref","first-page":"6426","DOI":"10.1158\/1078-0432.CCR-08-0702","article-title":"Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3","volume":"14","year":"2008","journal-title":"Clin Cancer Res"},{"key":"bib96-20230924","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gcc.20499","article-title":"TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma","volume":"47","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"bib97-20230924","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2004-06-2297","article-title":"MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B\u2013dependent proliferative advantage and resistance against FAS-induced cell death in B cells","volume":"105","year":"2005","journal-title":"Blood"},{"key":"bib98-20230924","first-page":"174","article-title":"cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas","volume":"116","year":"2006","journal-title":"J Clin Invest"},{"key":"bib99-20230924","first-page":"25","article-title":"MALT lymphomas: pathogenesis can drive treatment","volume":"1134\u201342","year":"2011","journal-title":"Oncology (Williston Park)"},{"key":"bib100-20230924","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1056\/NEJMoa033153","article-title":"Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell Lymphomas","volume":"351","year":"2004","journal-title":"N Engl J Med"},{"key":"bib101-20230924","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1198946","article-title":"Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation","volume":"331","year":"2011","journal-title":"Science"},{"key":"bib102-20230924","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.2004.10.087","article-title":"Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori\u2013independent status of early-stage, high-grade gastric mucosa\u2013associated lymphoid tissue lymphomas","volume":"22","year":"2004","journal-title":"J Clin Oncol"},{"key":"bib103-20230924","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/gut.2005.081117","article-title":"Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication","volume":"55","year":"2006","journal-title":"Gut"},{"key":"bib104-20230924","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00277-019-03671-5","article-title":"Mucosa-associated lymphoid tissue lymphoma with t(11;18)(q21;q21) translocation: long-term follow-up results","volume":"98","year":"2019","journal-title":"Ann Hematol"},{"key":"bib105-20230924","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2016-02-696757","article-title":"The genetics of nodal marginal zone lymphoma","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib106-20230924","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma","volume":"20","year":"2014","journal-title":"Nat Med"},{"key":"bib107-20230924","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/sj.leu.2403185","article-title":"Primary pulmonary MALT lymphomas show frequent and heterogeneous cytogenetic abnormalities, including aneuploidy and translocations involving API2 and MALT1 and IGH and MALT1","volume":"18","year":"2004","journal-title":"Leukemia"},{"key":"bib108-20230924","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/1098-2264(2000)9999:9999<::AID-GCC1048>3.0.CO;2-B","article-title":"Novel translocation of the BCL10 gene in a case of mucosa associated lymphoid tissue lymphoma","volume":"29","year":"2000","journal-title":"Genes Chromosomes Cancer"},{"key":"bib109-20230924","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nri1352","article-title":"CARMA1, BCL-10 and MALT1 in lymphocyte development and activation","volume":"4","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"bib110-20230924","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3324\/haematol.2011.054080","article-title":"BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas","volume":"97","year":"2012","journal-title":"Haematologica"},{"key":"bib111-20230924","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.12162","article-title":"Distinct involvement of NF-kappaB regulators by somatic mutation in ocular adnexal MALT lymphoma","volume":"160","year":"2013","journal-title":"Br J Haematol"},{"key":"bib112-20230924","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","year":"2011","journal-title":"Nature"},{"key":"bib113-20230924","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/leu.2012.257","article-title":"IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia\/lymphoplasmacytic lymphomas","volume":"27","year":"2013","journal-title":"Leukemia"},{"key":"bib114-20230924","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","year":"2013","journal-title":"Blood"},{"key":"bib115-20230924","first-page":"252318","article-title":"CD79B and MYD88 mutations in splenic marginal zone lymphoma","volume":"2013","year":"2013","journal-title":"ISRN Oncol"},{"key":"bib116-20230924","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1365-2141.2012.09176.x","article-title":"MYD88 somatic mutations in MALT lymphomas","volume":"158","year":"2012","journal-title":"Br J Haematol"},{"key":"bib117-20230924","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1182\/blood-2012-09-457101","article-title":"Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms","volume":"121","year":"2013","journal-title":"Blood"},{"key":"bib118-20230924","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/modpathol.2014.120","article-title":"MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma","volume":"28","year":"2015","journal-title":"Mod Pathol"},{"key":"bib119-20230924","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/PAS.0000000000000411","article-title":"MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma","volume":"39","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"bib120-20230924","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/leu.2013.365","article-title":"Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation","volume":"28","year":"2014","journal-title":"Leukemia"},{"key":"bib121-20230924","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1186\/s12885-015-1766-z","article-title":"Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations","volume":"15","year":"2015","journal-title":"BMC Cancer"},{"key":"bib122-20230924","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/leu.2014.294","article-title":"The Kruppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma","volume":"29","year":"2015","journal-title":"Leukemia"},{"key":"bib123-20230924","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/leu.2014.330","article-title":"KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype","volume":"29","year":"2015","journal-title":"Leukemia"},{"key":"bib124-20230924","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1084\/jem.20132203","article-title":"Identification of a human splenic marginal zone B cell precursor with NOTCH2-dependent differentiation properties","volume":"211","year":"2014","journal-title":"J Exp Med"},{"key":"bib125-20230924","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.4049\/jimmunol.171.6.2783","article-title":"NOTCH2 haploinsufficiency results in diminished B1 B cells and a severe reduction in marginal zone B cells","volume":"171","year":"2003","journal-title":"J Immunol"},{"key":"bib126-20230924","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4049\/jimmunol.179.1.195","article-title":"Synergism between NF-kappa B1\/p50 and NOTCH2 during the development of marginal zone B lymphocytes","volume":"179","year":"2007","journal-title":"J Immunol"},{"key":"bib127-20230924","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood-2018-99-115958","article-title":"Molecular subtypes of splenic marginal zone lymphoma (SMZL) are associated with distinct pathogenic mechanisms and outcomes\u2014interim analysis of the IELSG46 study","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib128-20230924","doi-asserted-by":"crossref","first-page":"e83244","DOI":"10.1371\/journal.pone.0083244","article-title":"Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"bib129-20230924","first-page":"382","article-title":"Absence of NOTCH1 gene mutations in MALT lymphomas","volume":"157","year":"2011","journal-title":"Br J Haematol"},{"key":"bib130-20230924","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/modpathol.2016.79","article-title":"Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies","volume":"29","year":"2016","journal-title":"Mod Pathol"},{"key":"bib131-20230924","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood-2014-08-596247","article-title":"DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib132-20230924","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood.V83.10.2829.2829","article-title":"Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome","volume":"83","year":"1994","journal-title":"Blood"},{"key":"bib133-20230924","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH727>3.0.CO;2-J","article-title":"Clone-specific PCR reveals wide dissemination of gastric MALT lymphoma to the gastric mucosa","volume":"192","year":"2000","journal-title":"J Pathol"},{"key":"bib134-20230924","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2559.1992.tb00912.x","article-title":"Low-grade gastric B-cell lymphoma of mucosa-associated lymphoid tissue (MALT): a multifocal disease","volume":"20","year":"1992","journal-title":"Histopathology"},{"key":"bib135-20230924","first-page":"241","article-title":"Hematology\/the education program of the American Society of Hematology. American Society of Hematology Education","year":"2001","journal-title":"Dent Prog"},{"key":"bib136-20230924","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/annonc\/mdm513","article-title":"Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy","volume":"19","year":"2008","journal-title":"Ann Oncol"},{"key":"bib137-20230924","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2002-04-1279","article-title":"Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","volume":"101","year":"2003","journal-title":"Blood"},{"key":"bib138-20230924","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00277-014-2042-z","article-title":"Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis","volume":"93","year":"2014","journal-title":"Ann Hematol"},{"key":"bib139-20230924","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1200\/JCO.2006.06.0723","article-title":"Assessment of disease dissemination in gastric compared with extragastric mucosa\u2013associated lymphoid tissue lymphoma using extensive staging: a single-center experience","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib140-20230924","first-page":"153","article-title":"Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","volume":"66","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"suppl 6","key":"bib141-20230924","first-page":"vi144","article-title":"Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","year":"2013","journal-title":"Ann Oncol"},{"key":"bib142-20230924","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","year":"2020","journal-title":"Ann Oncol"},{"key":"bib143-20230924","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.2152","article-title":"Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis","volume":"33","year":"2015","journal-title":"Hematol Oncol"},{"key":"bib144-20230924","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.clml.2019.10.006","article-title":"(18)F-FDG PET\/CT or PET role in MALT lymphoma: an open issue not yet solved\u2014a critical review","volume":"20","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"bib145-20230924","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.7150\/thno.31032","article-title":"Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [(68)Ga]Ga-pentixafor-PET\/MRI","volume":"9","year":"2019","journal-title":"Theranostics"},{"key":"bib146-20230924","doi-asserted-by":"crossref","first-page":"e104004","DOI":"10.1371\/journal.pone.0104004","article-title":"Clinical features, treatment and outcome of mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexa: single center experience of 60 patients","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"bib147-20230924","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hed.21533","article-title":"Clinicopathological aspects of mucosa-associated lymphoid tissue (MALT) lymphoma of the parotid gland: a retrospective single-center analysis of 28 cases","volume":"33","year":"2011","journal-title":"Head Neck"},{"key":"bib148-20230924","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1183\/09031936.00039309","article-title":"Clinical characteristics and prognostic factors of pulmonary MALT lymphoma","volume":"34","year":"2009","journal-title":"Eur Respir J"},{"key":"bib149-20230924","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/gut.2010.224949","article-title":"EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT","volume":"60","year":"2011","journal-title":"Gut"},{"key":"bib150-20230924","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib151-20230924","first-page":"194","article-title":"Splenic marginal zone lymphoma: current knowledge and future directions","volume":"26","year":"2012","journal-title":"Oncology (Williston Park)"},{"key":"bib152-20230924","first-page":"92","article-title":"Nodal marginal zone B-cell lymphoma: a diagnostic and therapeutic dilemma","volume":"26","year":"2012","journal-title":"Oncology (Williston Park)"},{"key":"bib153-20230924","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ajh.25473","article-title":"The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas","volume":"94","year":"2019","journal-title":"Am J Hematol"},{"key":"bib154-20230924","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.1997.15.4.1624","article-title":"Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients","volume":"15","year":"1997","journal-title":"J Clin Oncol"},{"key":"bib155-20230924","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00000478-199608000-00010","article-title":"Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients","volume":"20","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"bib156-20230924","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/0016-5085(92)91723-H","article-title":"Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis","volume":"102","year":"1992","journal-title":"Gastroenterology"},{"key":"bib157-20230924","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0344-0338(11)80904-0","article-title":"Factors influencing lymph node infiltration in primary gastric malignant lymphoma of the mucosa-associated lymphoid tissue","volume":"190","year":"1994","journal-title":"Pathol Res Pract"},{"key":"bib158-20230924","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/oxfordjournals.annonc.a058388","article-title":"Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: the Milan Cancer Institute Experience","volume":"4","year":"1993","journal-title":"Ann Oncol"},{"key":"bib159-20230924","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A MALT lymphoma prognostic index","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib160-20230924","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2017-07-795302","article-title":"Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib161-20230924","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00277-018-3516-1","article-title":"Validation of the marginal zone lymphoma International Prognostic Index","volume":"98","year":"2019","journal-title":"Ann Hematol"},{"key":"bib162-20230924","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ajh.25446","article-title":"Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation","volume":"94","year":"2019","journal-title":"Am J Hematol"},{"key":"bib163-20230924","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/hon.136_2629","article-title":"Early progression of disease (POD24) predicts shorter survival in MALT lymphoma patients receiving systemic treatment","volume":"37","year":"2019","journal-title":"Hematol Oncol"},{"key":"bib164-20230924","first-page":"Jco1800138","article-title":"Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib165-20230924","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Splenic marginal zone lymphoma: a prognostic model for clinical use","volume":"107","year":"2006","journal-title":"Blood"},{"key":"bib166-20230924","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.12011","article-title":"Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases","volume":"159","year":"2012","journal-title":"Br J Haematol"},{"key":"bib167-20230924","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3109\/10428194.2013.818143","article-title":"Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use","volume":"55","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"bib168-20230924","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjh.15641","article-title":"Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA\/IELSG36 study","volume":"183","year":"2018","journal-title":"Br J Haematol"},{"key":"bib169-20230924","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11864-019-0687-5","article-title":"Marginal zone lymphoma: state-of-the-art treatment","volume":"20","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"bib170-20230924","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","article-title":"The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib171-20230924","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.beha.2017.01.001","article-title":"Bacteria associated with marginal zone lymphomas","volume":"30","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"bib173-20230924","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2013-02-486522","article-title":"Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature","volume":"122","year":"2013","journal-title":"Blood"},{"key":"bib174-20230924","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/annonc\/mdx025","article-title":"Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib175-20230924","first-page":"58","article-title":"Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: Consortium for Improving Survival of Lymphoma (CISL) study","volume":"39","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"bib176-20230924","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.clml.2011.04.009","article-title":"Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma","volume":"11","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"bib177-20230924","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3109\/10428194.2015.1099650","article-title":"A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial","volume":"57","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"bib178-20230924","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","year":"2003","journal-title":"Blood"},{"key":"bib179-20230924","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"bib180-20230924","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib181-20230924","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/hon.2437_136","article-title":"Immunochemotherapy with obinutuzumab or rituximab in a subset of patients in the randomised gallium trial with previously untreated marginal zone lymphoma (MZL)","volume":"35","year":"2017","journal-title":"Hematol Oncol"},{"key":"bib182-20230924","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hon.2555","article-title":"Treatment of mucosa associated lymphoid tissue lymphoma with a long-term once-weekly regimen of oral azithromycin: results from the phase II MALT-A trial","volume":"37","year":"2019","journal-title":"Hematol Oncol"},{"journal-title":"Am J Hematol","article-title":"Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study","year":"2019","key":"bib183-20230924"},{"key":"bib184-20230924","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib185-20230924","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.15552","article-title":"An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma","volume":"184","year":"2019","journal-title":"Br J Haematol"},{"key":"bib186-20230924","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hon.2454","article-title":"A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma","volume":"36","year":"2018","journal-title":"Hematol Oncol"},{"key":"bib187-20230924","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib188-20230924","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2016.154377","article-title":"Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study","volume":"102","year":"2017","journal-title":"Haematologica"},{"key":"bib189-20230924","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2015-0176","article-title":"Delayed efficacy after treatment with lenalidomide or thalidomide in patients with mucosa-associated lymphoid tissue lymphoma","volume":"21","year":"2016","journal-title":"Oncologist"},{"key":"bib190-20230924","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/annonc\/mdv214","article-title":"High-dose clarithromycin is an active monotherapy for patients with relapsed\/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial","volume":"26","year":"2015","journal-title":"Ann Oncol"},{"key":"bib191-20230924","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2141.2010.08179.x","article-title":"Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-Centre phase II trial","volume":"150","year":"2010","journal-title":"Br J Haematol"},{"key":"bib192-20230924","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/hon.2078","article-title":"Efficacy of 90yttrium-ibritumomab tiuxetan in relapsed\/refractory extranodal marginal-zone lymphoma","volume":"32","year":"2014","journal-title":"Hematol Oncol"},{"key":"bib193-20230924","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.13021","article-title":"90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease","volume":"167","year":"2014","journal-title":"Br J Haematol"},{"key":"bib194-20230924","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bjh.12630","article-title":"Phase IA\/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma","volume":"164","year":"2014","journal-title":"Br J Haematol"},{"key":"bib195-20230924","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.12845","article-title":"Clinical activity of everolimus in relapsed\/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group","volume":"166","year":"2014","journal-title":"Br J Haematol"},{"key":"bib196-20230924","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1182\/blood.V126.23.1543.1543","article-title":"Idelalisib monotherapy and durable responses in patients with relapsed or refractory marginal zone lymphoma (MZL)","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib197-20230924","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"bib198-20230924","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"bib199-20230924","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/annonc\/mdq416","article-title":"Clinical activity of bortezomib in relapsed\/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)","volume":"22","year":"2011","journal-title":"Ann Oncol"},{"key":"bib200-20230924","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10637-009-9260-6","article-title":"Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial","volume":"28","year":"2010","journal-title":"Invest New Drugs"},{"key":"bib201-20230924","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2009-08-233155","article-title":"Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma","volume":"115","year":"2010","journal-title":"Blood"},{"key":"bib202-20230924","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","year":"2010","journal-title":"Blood"},{"key":"bib203-20230924","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1200\/JCO.2008.19.9117","article-title":"Humanized anti-CD20 antibody, veltuzumab, in refractory\/recurrent non-Hodgkin's lymphoma: phase I\/II results","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib204-20230924","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1600-0609.2008.01197.x","article-title":"Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies","volume":"82","year":"2009","journal-title":"Eur J Haematol"},{"key":"bib205-20230924","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2008.001537","article-title":"A phase II study of bortezomib in patients with MALT lymphoma","volume":"94","year":"2009","journal-title":"Haematologica"},{"key":"bib206-20230924","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1200\/JCO.2005.05.3470","article-title":"Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib207-20230924","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/annonc\/mdl126","article-title":"Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial","volume":"17","year":"2006","journal-title":"Ann Oncol"},{"key":"bib208-20230924","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","article-title":"Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti\u2013Helicobacter pylori therapy","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib209-20230924","doi-asserted-by":"crossref","first-page":"8442","DOI":"10.1200\/JCO.2004.00.8532","article-title":"Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib210-20230924","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.2005.00426.x","article-title":"Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes","volume":"75","year":"2005","journal-title":"Eur J Haematol"},{"key":"bib211-20230924","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib212-20230924","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib213-20230924","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3109\/10428199809057569","article-title":"Cladribine for untreated or early low-grade non-Hodgkin's lymphoma","volume":"30","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"bib214-20230924","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/bjh.15814","article-title":"Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma","volume":"185","year":"2019","journal-title":"Br J Haematol"},{"key":"bib215-20230924","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/bjh.15843","article-title":"Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial","volume":"185","year":"2019","journal-title":"Br J Haematol"},{"key":"bib216-20230924","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2016-06-720599","article-title":"A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib217-20230924","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/ajh.24693","article-title":"A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy","volume":"92","year":"2017","journal-title":"Am J Hematol"},{"key":"bib218-20230924","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.3109\/10428194.2015.1029925","article-title":"Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study","volume":"56","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"bib219-20230924","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3324\/haematol.2014.117473","article-title":"A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"100","year":"2015","journal-title":"Haematologica"},{"key":"bib220-20230924","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.13637","article-title":"A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma","volume":"171","year":"2015","journal-title":"Br J Haematol"},{"key":"bib221-20230924","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/cncr.28405","article-title":"Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas","volume":"120","year":"2014","journal-title":"Cancer"},{"key":"bib222-20230924","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/bjh.12991","article-title":"Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma","volume":"166","year":"2014","journal-title":"Br J Haematol"},{"key":"bib223-20230924","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3324\/haematol.2012.072587","article-title":"Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie","volume":"98","year":"2013","journal-title":"Haematologica"},{"key":"bib224-20230924","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00277-011-1337-6","article-title":"Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study","volume":"91","year":"2012","journal-title":"Ann Hematol"},{"key":"bib225-20230924","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00277-011-1199-y","article-title":"Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue","volume":"90","year":"2011","journal-title":"Ann Hematol"},{"key":"bib226-20230924","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2141.2009.07677.x","article-title":"A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas","volume":"145","year":"2009","journal-title":"Br J Haematol"},{"key":"bib227-20230924","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.24605","article-title":"Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type","volume":"115","year":"2009","journal-title":"Cancer"},{"key":"bib228-20230924","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","article-title":"Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"bib229-20230924","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/cncr.23236","article-title":"A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma","volume":"112","year":"2008","journal-title":"Cancer"},{"key":"bib230-20230924","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/10428190701784714","article-title":"Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma","volume":"49","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"bib231-20230924","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","article-title":"Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib232-20230924","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"bib233-20230924","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1080\/1042819042000223822","article-title":"Fludarabine and bendamustine in refractory and relapsed indolent lymphoma\u2014a multicenter phase I\/II trial of the East German Society of Hematology and Oncology (OSHO)","volume":"45","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"bib234-20230924","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.semcancer.2016.07.003","article-title":"MALT lymphoma: a paradigm of NF-\u03baB dysregulation","volume":"39","year":"2016","journal-title":"Semin Cancer Biol"},{"key":"bib235-20230924","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semcancer.2016.08.002","article-title":"NF-\u03baB deregulation in splenic marginal zone lymphoma","volume":"39","year":"2016","journal-title":"Semin Cancer Biol"},{"key":"bib236-20230924","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrclinonc.2016.205","article-title":"The landscape of new drugs in lymphoma","volume":"14","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"bib237-20230924","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib238-20230924","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/10428194.2013.845884","article-title":"Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?","volume":"55","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"bib239-20230924","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2018-02-833608","article-title":"Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib240-20230924","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.seminhematol.2010.01.004","article-title":"Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab","volume":"47","year":"2010","journal-title":"Semin Hematol"},{"key":"bib241-20230924","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00277-013-1900-4","article-title":"Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma","volume":"93","year":"2014","journal-title":"Ann Hematol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T15:38:47Z","timestamp":1723304327000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":236,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000463","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"type":"electronic","value":"1540-336X"},{"type":"print","value":"1528-9117"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}